Star Combo Pharma (ASX:S66) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:S66 Star Combo Pharma Ltd ASX:S66
35 GF Score
Price A$0.13
GF Value A$0.13
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Star Combo Pharma Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Star Combo Pharma is: High Risk: High uncertainty with risk-return tradeoff.

Star Combo Pharma  (ASX:S66) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Star Combo Pharma Risk Assessment Related Terms

ASX:S66 vs PG, CL, KVUE: Risk Assessment Comparison

For the Household & Personal Products subindustry, Star Combo Pharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Star Combo Pharma Risk Assessment vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Star Combo Pharma's Risk Assessment falls into.


ASX:S66
35GF Score
Star Combo Pharma Ltd ASX:S66
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Star Combo Pharma (ASX:S66) Overvalued in 2026?

Based on GuruFocus' analysis, Star Combo Pharma stock appears to be undervalued. The current stock price of A$0.13 is trading 0% below its estimated GF Value™ of A$0.13. GuruFocus considers Star Combo Pharma to be Fairly Valued.

Key valuation signals for ASX:S66:

  • Risk Assessment:
  • GF Value™: A$0.13 vs. price of A$0.13 (0% below fair value)
  • GF Score™: 35/100 with 2 warning signs

No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Star Combo Pharma Business Description

Address 171 - 177 Woodpark Road, Smithfield, Sydney, NSW, AUS, 2164
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
35GF Score

Get the complete analysis for ASX:S66

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price
A$0.13
GF Value